Intraperitoneal Hyperthermic Chemoperfusion (IPHC / HIPEC)

Intraperitoneal hyperthermic chemoperfusion (IPHC) is a specialized hyperthermia therapy used along with surgery
for treating advanced abdominal cancers. In this procedure, warmed anti-cancer drugs are circulated in the peritoneal cavity
for a limited period. Commonly used drugs include mitomycin-C and cisplatin.

IPHC is also known as HIPEC (Hyperthermic Intraperitoneal Chemotherapy),
intra-abdominal hyperthermic chemoperfusion, intraoperative chemohyperthermic peritoneal perfusion (CHPP),
or the Sugarbaker technique, after Dr. Paul Sugarbaker who pioneered this approach.

Our specialized team performs this advanced procedure —
we are the only center in the Middle East & North Africa (MENA) offering such high-quality HIPEC treatment (besides Riyadh, KSA).
A multidisciplinary approach ensures individualized care and the best treatment outcomes.

Procedure Stages

1. Exploration: The surgeon opens the abdomen to evaluate peritoneal cancer.
2. Debulking (Cytoreduction): Visible tumor implants are removed. Even after removal, microscopic cancer cells may remain.
3. Chemoperfusion: The abdominal cavity is rinsed with a heated chemotherapy solution.
   Unlike systemic chemotherapy, HIPEC delivers high drug concentration locally, minimizing toxicity and side effects.

Points of Interest to Patients

• Peritoneal carcinomatosis
• Pseudomyxoma peritonei
• Mucinous adenocarcinoma of appendix
• Colorectal cancer with local infiltration
• Mesothelioma & pleural mesothelioma
• Gastric carcinomatosis
• HIPEC & CRS (Cytoreductive Surgery)
• Hyperthermic chemotherapy
• Debulking surgery
• Clinical trials
• Low-grade sarcoma
• Ovarian carcinomatosis
• Multidisciplinary team (MDT) management
• Intraoperative ultrasound
• Genomic profiling
• Center of Excellence in peritonectomy
• Chemotherapy infusion & staged procedures
• Adhesiolysis
• Risk and complications counseling

Pictures of Recently Performed Surgeries

Please click on the text to view:

• Appendix tumor in peritoneal surface malignancy.
• Cleaning the peritoneal implant after Hipec therapy for colon cancer metastasis.
• Peritoneal carcinomatosis in gastric cancer prior to neoadjuvent treatment for HIPC therapy (2).
• Peritoneal carcinomatosis in gastric cancer prior to neoadjuvent treatment for HIPC therapy (3).
• Peritoneal carcinomatosis in gastric cancer prior to neoadjuvent treatment for HIPC therapy.